Patrick Mufarrij, MD
Urology · Washington, DCNPI 1992900526
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Travere Therapeutics, Inc. at 59.7% of the total. Reporting peaked in 2019 at $19,182 and has fallen 97.8% since, to $426 in 2025. Among urology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $201.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$19K
- Cook Incorporated$4K
- Gyrus ACMI, Inc.$3K
- Cook Medical LLC$3K
- Coloplast$713
- Olympus America Inc.$565
- plus $2K from 18 others
What the payments were for
- Consulting fees$12,23039%
- Speaking & faculty fees$10,90035%
- Travel & lodging$1,6465%
- Food & beverage$6,22720%
- Education$2041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 26 | $18,626 |
| Cook Incorporated | 1 | $3,500 |
| Gyrus ACMI, Inc. | 10 | $3,456 |
| Cook Medical LLC | 49 | $2,629 |
| Coloplast | 10 | $713 |
| Olympus America Inc. | 7 | $565 |
| Astellas Pharma US Inc | 17 | $444 |
| Richard Wolf Medical Instruments Corp. | 1 | $201 |
| Alnylam Pharmaceuticals Inc. | 8 | $190 |
| Neotract Inc. | 1 | $137 |
| Ambu Inc. | 2 | $134 |
| Boston Scientific | 5 | $122 |
| Johnson & Johnson | 1 | $118 |
| KARL Storz Endoscopy-america | 3 | $88 |
| 180 Medical, Inc. | 2 | $48 |
| Urovant Sciences Inc | 2 | $42 |
| Pfizer | 2 | $33 |
| Merck | 1 | $30 |
| Telix Pharmaceuticals | 1 | $24 |
| Teleflex LLC | 1 | $24 |
| Mission Pharmacal Company | 2 | $23 |
| Palette Life Sciences, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Hollister Incorporated | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (815) Thiola$17,368
- Cook Medical Dilation/Access$3,500
- Olympus Laser Devices$3,330
- Porges Coloplast$316
- LITHO 150$315
- FIBER DUST$272
- Cook Medical Urology$254
- Cook$247
- NGage$225
- RETRACE$139
- Olympus$139
- UroLift$137
- UGN Laser Capital$122
- Ultrasonic Generators$122
- Monarch Platform$118
- Soltive$117
- GENERAL - THERAPIES$108
- iTIND System$103
How this compares
$31,208 in reported general payments places this provider in the 90th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 139 | $31,403 |
| MyrbetriqMirabegron | 41 | $24,732 |
| Tamsulosin Hcl | 109 | $2,421 |
| Methenamine Hippurate | 12 | $1,227 |
| Finasteride | 44 | $1,152 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $841 |
| CefuroximeCefuroxime Axetil | 56 | $829 |
| Chlorthalidone | 26 | $623 |
| Indapamide | 18 | $409 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 46 | $258 |
| Ondansetron OdtOndansetron | 16 | $205 |
| Sildenafil Citrate | 14 | $182 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $177 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $148 |
| Diazepam | 20 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $444 | $24,73241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 47 urology providers in District of Columbia.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Ryan HankinsWashington$29K
- Adam MetwalliWashington$27K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Jason EngelWashington$12K
- Keith KowalczykWashington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.